Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerHead and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, squamous cell carcinomaActive, not recruitingPhase 12026-08-21NCT04576091

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Duke University Medical CenterDurhamUnited States505
Huntsman Cancer Institute/University of UtahSalt Lake CityUnited States249
Los Angeles General Medical CenterLos AngelesUnited States179
Montefiore Medical Center - Moses CampusThe BronxUnited States219
Montefiore Medical Center-Einstein CampusThe BronxUnited States170
Northwestern UniversityChicagoUnited States727
University of Michigan Rogel Cancer CenterAnn ArborUnited States186
University of Oklahoma Health Sciences CenterOklahoma CityUnited States491
UPMC Hillman Cancer CenterPittsburghUnited States330
USC / Norris Comprehensive Cancer CenterLos AngelesUnited States249
Vanderbilt University/Ingram Cancer CenterNashvilleUnited States259